CONTRAVE contains bupropion, the same active ingredient as some other antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR
, WELLBUTRIN XL and APLENZIN).
Bupropion, the generic name for the brand Wellbutrin SR
is marketed in the US by Glaxo Smithkline.
The indictment doesn't name the company, but GlaxoSmithKline has confirmed Stevens is now retired from its law department and the drug in question was Wellbutrin SR
Bupropion HCl SR tablets, the generic equivalent of GlaxoSmithKline's Wellbutrin SR
, are now available from Actavis in the following strengths: 100mg, 150mg, and 200mg.
unit had received approval to market a generic version of GlaxoSmithKline Plc's Wellbutrin SR
extended release tablets.
Wellbutrin XL once daily maintains bupropion plasma concentrations over 24 hours, helping to eliminate the evening peak in bupropion levels seen with Wellbutrin SR
Glaxo, which employs 2,200 people at factories in County Durham and Cumbria, said generic versions of Wellbutrin SR
and Paxil IR had cost it over pounds 1.
Drugs with significant potential that are having generic equivalents hit the market are: Ortho-Novum 7/7/7 * (birth control) Ortho Tri-Clyclen * (birth control) Accupril (blood pressure) Nolvadex (breast cancer) Topamax (anti-convulsant) Glucophage XR (diabetes) Monopril (blood pressure) Remeron (antidepressant) Alphagan (glaucoma) Serzone (antidepressant) Glucovance (diabetes) Glucotrol XL (diabetes) Wellbutrin SR
(antidepressant) Zyban (smoking cessation) Neurontin (anti-convulsant) Tiazac (blood pressure) Prozac (antidepressant) Prilosec (gastritis)
Bupropion - sold as Zyban and Wellbutrin SR
- has emerged as a front- line treatment since receiving approval as a smoking cessation aid by the Food and Drug Administration in 1997.
GlaxoSmithKline dropped 16p to 1250p on fears that its antidepressant Wellbutrin SR
could face US competition.
Should not be given to patients already taking Welibutrin or Wellbutrin SR
, as these also contain bupropion.
The first, Wellbutrin SR
, is a buproprion hydrochloride extended-release tablet marketed by Glaxo Wellcome, Inc.